Prognostic value of serum beta(2)-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3114852 22 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Prognostic value of serum beta(2)-microglobulin in patients with
Waldenstrom's macroglobulinemia requiring treatment
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: Waldenstrom’s macroglobulinemia (WM) is a lymphoplasmacytoid
lymphoma characterized by a relatively indolent course with median
survival ranging from 5 years to 10 years in different series. Several
clinical and laboratory variables have been associated with inferior
survival, such as advanced age, hyperviscosity, presence of cytopenia,
and hypoalbuminemia. Recent data indicate that serum
beta(2)-microglobulin (beta 2M) might also be significant. The purpose
of our study was to assess possible correlations of beta 2M with
clinical and laboratory variables and to further evaluate its
association with cause-specific and overall survival (OS) of patients
with WM requiring treatment. Patients and Methods: We analyzed 124
patients with WM with an available pretreatment value of beta 2M. Median
age was 70 years (range, 28-89 years), and median survival was 105
months. Multiple clinical and laboratory parameters were evaluated for
their possible correlation with OS. Results: Patients with older age,
anemia, thrombocytopenia, hypoalbuminemia, and higher creatinine levels
had significantly greater serum beta 2M levels. This variable was
associated with impaired cause-specific survival and OS in the whole
group of patients and in patients aged <= 70 years. More specifically,
OS for all patients according to serum beta 2M > 4 mg/dL versus <= 4
mg/dL was 79 months versus 115 months (P = 0.01). Conclusion: Our data
provide further evidence that high beta 2M levels are an important
parameter associated with inferior OS and cause-specific survival of
patients with WM requiring treatment. This parameter may be used to
stratify patients involved in prospective clinical trials.
Έτος δημοσίευσης:
2006
Συγγραφείς:
Anagnostopoulos, Athanasios
Zervas, Konstantinos
Kyrtsonis,
Marie Christine
Symeonidis, Argyris
Gika, Dimitra
Bourantas,
Konstantinos
Zomas, Athanasios
Anagnostopoulos, Nikolaos and
Pangalis, Gerasimos
Dimopoulos, Meletios Athanasios
Greek
Myeloma Study Grp
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
CIG MEDIA GROUP, LP
Τόμος:
7
Αριθμός / τεύχος:
3
Σελίδες:
205-209
Λέξεις-κλειδιά:
anemia; B symptoms; hyperviscosity; lymphadenopathy; splenomegaly
Επίσημο URL (Εκδότης):
DOI:
10.3816/CLM.2006.n.060
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.